Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
In a step towards the commercialisation of its ‘off-the-shelf’ CAR-T therapies, Cellectis begins construction of a facility in France and enters lease agreement for US facility.